A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Adalimumab-Adbm (Cyltezo)

First FDA approval2023-07-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$143.7M in CY2024 Part D spend20K claims · 6K beneficiaries · 329 plans surveyed

Lowest NADAC
$636.22/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1490.55
Across all dosage forms in distribution.
Highest NADAC
$3199.19
Wide spread — brand-strength NDCs still in market.
Plans with PA
606 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Adalimumab-Adbm used for?

Adalimumab-Adbm is a this drug class medication tracked in Medicare Part D.

Is there a generic for Adalimumab-Adbm?

No. Adalimumab-Adbm is brand-only with no generic equivalents currently in market.

How much does my plan pay for Adalimumab-Adbm?

Across 329 Part D plans, Adalimumab-Adbm averages $1490.55/unit (NADAC). Lowest available: $636.22/unit. Highest in distribution: $3199.19/unit.

Is Adalimumab-Adbm on the FDA shortage list?

No. Adalimumab-Adbm is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Drug class1 alternative in D1
01
Adalimumab
Brand: HUMIRA
$872.45Lowest NADAC
0Generic mfrs
$8.57BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.